MedTrace Logo

Evaluation of Endocrine Therapy Effects of Host Immunity in Early Stage Breast Cancer

NCT03719495 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 68

Last updated 2024-05-16

No results posted yet for this study

Summary

The purpose of this research study is to learn about the effects that standard of care endocrine therapies have on the immune system's response to cancer by looking at the number and types of immune cells present and how they function in women with early stage estrogen receptor positive (ER+) breast cancer.

Conditions

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Duke University

    lead OTHER

Principal Investigators

  • Susan Dent, MD · Duke University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-06-19
Primary Completion
2023-07-31
Completion
2023-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03719495 on ClinicalTrials.gov